The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
The state-of-play and future of platinum drugs
Abstract
The year 2015 marks the 50th anniversary since the discovery of the anticancer potential of cisplatin and it remains just as useful now as it did back then, especially for the treatment of some endocrine-related cancers like ovarian and testicular carcinomas. Since its discovery, five other platin drugs have received approval in various countries. While several new platin drugs are in preclinical development, in the last decade only two new platin drugs have entered clinical trials, LA-12 and dicycloplatin, reflecting a shift in research focus from new drug design to improved formulations of already approved platin drugs. These formulations include their encapsulation with macrocycles to slow and prevent their degradation by proteins and peptides; their attachment to nanoparticles to passively target solid tumours through the enhanced permeability and retention effect and their coordination to important nutrients, proteins, antibodies and aptamers for active tumour targeting. These formulation methods have all shown potential but none have yet yielded a new marketable medicine containing a platin drug. The reasons for this are problems of consistent drug loading, controlling the location and timing of drug release and the inherent toxicity of some of the drug delivery vehicles. In addition to drug delivery, functional genomics is now playing an increasing role in predicting patients' responses to platin chemotherapy and their likelihood of experiencing severe side effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cisplatin in cancer therapy: Molecular mechanisms of action
Dasari, S., & Bernard Tchounwou, P. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.025 · Cited by 5,537
Fang, J., Nakamura, H., & Maeda, H. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.04.009 · Cited by 3,559
Molecular mechanisms of cisplatin resistance
Galluzzi, L., Senovilla, L., Vitale, I., Michels, J., Martins, I., Kepp, O., Castedo, M., & Kroemer, G. (2012) · Oncogene · doi:10.1038/onc.2011.384 · Cited by 2,760 · cited 19×
“As the drug has only one labile ligand, it is only capable of forming monofunctional adducts with DNA.”
InfluentialPoland, C. A., Duffin, R., Kinloch, I., Maynard, A., Wallace, W. A. H., Seaton, A., Stone, V., Brown, S., MacNee, W., & Donaldson, K. (2008) · Nature Nanotechnology · doi:10.1038/nnano.2008.111 · Cited by 2,645
Tumor delivery of macromolecular drugs based on the EPR effect
Torchilin, V. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.03.011 · Cited by 2,032
Cyclodextrin-based pharmaceutics: past, present and future
Davis, M. E., & Brewster, M. E. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1576 · Cited by 1,996
Gold nanoparticles in biomedical applications: recent advances and perspectives
Dykman, L., & Khlebtsov, N. (2012) · Chem. Soc. Rev. · doi:10.1039/c1cs15166e · Cited by 1,961
The status of platinum anticancer drugs in the clinic and in clinical trials
Wheate, N. J., Walker, S., Craig, G. E., & Oun, R. (2010) · Dalton Transactions · doi:10.1039/c0dt00292e · Cited by 1,634
Self-citationCucurbiturils: from synthesis to high-affinity binding and catalysis
Assaf, K. I., & Nau, W. M. (2015) · Chemical Society Reviews · doi:10.1039/c4cs00273c · Cited by 1,368
Dhar, S., Gu, F. X., Langer, R., Farokhzad, O. C., & Lippard, S. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809154105 · Cited by 994
Gold Nanoparticles for the Improved Anticancer Drug Delivery of the Active Component of Oxaliplatin
Brown, S. D., Nativo, P., Smith, J.-A., Stirling, D., Edwards, P. R., Venugopal, B., Flint, D. J., Plumb, J. A., Graham, D., & Wheate, N. J. (2010) · Journal of the American Chemical Society · doi:10.1021/ja908117a · Cited by 865
Self-citationBhirde, A. A., Patel, V., Gavard, J., Zhang, G., Sousa, A. A., Masedunskas, A., Leapman, R. D., Weigert, R., Gutkind, J. S., & Rusling, J. F. (2009) · ACS Nano · doi:10.1021/nn800551s · Cited by 853
Metal-based antitumour drugs in the post genomic era
Dyson, P. J., & Sava, G. (2006) · Dalton Transactions · doi:10.1039/b601840h · Cited by 771
Dhar, S., Liu, Z., Thomale, J., Dai, H., & Lippard, S. J. (2008) · Journal of the American Chemical Society · doi:10.1021/ja803036e · Cited by 700
Feazell, R. P., Nakayama-Ratchford, N., Dai, H., & Lippard, S. J. (2007) · Journal of the American Chemical Society · doi:10.1021/ja073231f · Cited by 616
Supramolecular Chemistry of p-Sulfonatocalix[n]arenes and Its Biological Applications
Guo, D.-S., & Liu, Y. (2014) · Accounts of Chemical Research · doi:10.1021/ar500009g · Cited by 613
Dendrimers in Oncology: An Expanding Horizon
Tekade, R. K., Kumar, P. V., & Jain, N. K. (2009) · Chemical Reviews · doi:10.1021/cr068212n · Cited by 466
Folate-targeted therapies for cancer
Xia, W., & Low, P. S. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100509v · Cited by 448
Isakoff, S. J., Mayer, E. L., He, L., Traina, T. A., Carey, L. A., Krag, K. J., Rugo, H. S., Liu, M. C., Stearns, V., Come, S. E., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.6660 · Cited by 436
Reversible Cell‐Specific Drug Delivery with Aptamer‐Functionalized Liposomes
Cao, Z., Tong, R., Mishra, A., Xu, W., Wong, G. C. L., Cheng, J., & Lu, Y. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200901452 · Cited by 372
What do we know about the reduction of Pt(IV) pro-drugs?
Wexselblatt, E., & Gibson, D. (2012) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2012.06.013 · Cited by 370
Moghaddam, S., Yang, C., Rekharsky, M., Ko, Y. H., Kim, K., Inoue, Y., & Gilson, M. K. (2011) · Journal of the American Chemical Society · doi:10.1021/ja109904u · Cited by 344
Understanding and improving platinum anticancer drugs--phenanthriplatin.
Johnstone, T. C., Park, G. Y., & Lippard, S. J. (2014) · PubMed · Cited by 337
Park, G. Y., Wilson, J. J., Song, Y., & Lippard, S. J. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1207670109 · Cited by 330
Targeting carbon nanotubes against cancer
Fabbro, C., Ali-Boucetta, H., Ros, T. D., Kostarelos, K., Bianco, A., & Prato, M. (2012) · Chemical Communications · doi:10.1039/c2cc17995d · Cited by 281
Advances in Platinum Chemotherapeutics
Harper, B. W., Krause‐Heuer, A. M., Grant, M. P., Manohar, M., Garbutcheon‐Singh, K. B., & Aldrich‐Wright, J. R. (2010) · Chemistry – A European Journal · doi:10.1002/chem.201000148 · Cited by 267
Nucleic acid aptamers in cancer research, diagnosis and therapy
Ma, H., Liu, J., Ali, M. M., Mahmood, M. A. I., Labanieh, L., Lu, M., Iqbal, S. M., Zhang, Q., Zhao, W., & Wan, Y. (2015) · Chemical Society Reviews · doi:10.1039/c4cs00357h · Cited by 265
Aptamer Nanomedicine for Cancer Therapeutics: Barriers and Potential for Translation
Lao, Y.-H., Phua, K. K. L., & Leong, K. W. (2015) · ACS Nano · doi:10.1021/nn507494p · Cited by 259
Optimization and Modifications of Aptamers Selected from Live Cancer Cell Lines
Shangguan, D., Tang, Z., Mallikaratchy, P., Xiao, Z., & Tan, W. (2007) · ChemBioChem · doi:10.1002/cbic.200600532 · Cited by 250
Handbook of Pharmaceutical Excipients
Press, P. (2012) · Pharmacy Practice · Cited by 235
Lipoplatin Formulation Review Article
Stathopoulos, G. P., & Boulikas, T. (2012) · Journal of Drug Delivery · doi:10.1155/2012/581363 · Cited by 224
Folate-Targeted PEG as a Potential Carrier for Carboplatin Analogs. Synthesis and in Vitro Studies
Aronov, O., Horowitz, A. T., Gabizon, A., & Gibson, D. (2003) · Bioconjugate Chemistry · doi:10.1021/bc025642l · Cited by 198
Dendrimers and nanomedicine: multivalency in action
Rolland, O., Turrin, C.-O., Caminade, A.-M., & Majoral, J.-P. (2009) · New Journal of Chemistry · doi:10.1039/b901054h · Cited by 187
Platinum compounds in children with cancer
Ruggiero, A., Trombatore, G., Triarico, S., Arena, R., Ferrara, P., Scalzone, M., Pierri, F., & Riccardi, R. (2013) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e3283650bda · Cited by 139
Wagstaff, A. J., Brown, S. D., Holden, M., Craig, G. E., Plumb, J. A., Brown, R. E., Schreiter, N., Chrzanowski, W., & Wheate, N. (2012) · Inorganica Chimica Acta · doi:10.1016/j.ica.2012.05.012 · Cited by 136
Self-citationCommon variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss
Xu, H., Robinson, G. W., Huang, J., Lim, J. Y.-S., Zhang, H., Bass, J. K., Broniscer, A., Chintagumpala, M., Bartels, U. K., Gururangan, S., et al. (2015) · Nature Genetics · doi:10.1038/ng.3217 · Cited by 135
Craig, G. E., Brown, S. D., Lamprou, D. A., Graham, D., & Wheate, N. (2012) · Inorganic Chemistry · doi:10.1021/ic202197g · Cited by 122
Self-citationModelling the encapsulation of the anticancer drug cisplatin into carbon nanotubes
Hilder, T. A., & Hill, J. M. (2007) · Nanotechnology · doi:10.1088/0957-4484/18/27/275704 · Cited by 110
Kirkpatrick, G. J., Plumb, J. A., Sutcliffe, O. B., Flint, D. J., & Wheate, N. (2011) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2011.05.017 · Cited by 105
Self-citationBose, R. N., Maurmann, L., Mishur, R. J., Yasui, L. S., Gupta, S., Grayburn, W. S., Hofstetter, H., & Salley, T. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803094105 · Cited by 98
Osman, A. A., Neskey, D. M., Katsonis, P., Patel, A. A., Ward, A. M., Hsu, T., Hicks, S. C., McDonald, T. O., Ow, T. J., Alves, M. V. O., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2729 · Cited by 92
Early cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulation
de Jonge, M. J. A., Slingerland, M., Loos, W. J., Wiemer, E. A. C., Burger, H., Mathijssen, R. H. J., Kroep, J. R., den Hollander, M., van der Biessen, D. A. J., Lam, M.-H., et al. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.07.015 · Cited by 92
Cyclodextrin Capped Gold Nanoparticles as a Delivery Vehicle for a Prodrug of Cisplatin
Shi, Y., Goodisman, J., & Dabrowiak, J. C. (2013) · Inorganic Chemistry · doi:10.1021/ic400989v · Cited by 92
Jensen, S. S., Andresen, T. L., Davidsen, J. R., Høyrup, P., Shnyder, S. D., Bibby, M. C., Gill, J. H., & Jørgensen, K. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1451.3.11 · Cited by 86
Encapsulation into Carbon Nanotubes and Release of Anticancer Cisplatin Drug Molecule
Méjri, A., Vardanega, D., Tangour, B., Gharbi, T., & Picaud, F. (2014) · The Journal of Physical Chemistry B · doi:10.1021/jp5102384 · Cited by 86
Krause‐Heuer, A. M., Wheate, N., Tilby, M. J., Pearson, D. G., Ottley, C. J., & Aldrich-Wright, J. R. (2008) · Inorganic Chemistry · doi:10.1021/ic800467c · Cited by 84
Self-citationMassaguer, A., González-Cantó, A., Escribano, E., Barrabés, S., Artigas, G., Moreno, V., & Marchán, V. (2014) · Dalton Transactions · doi:10.1039/c4dt02710h · Cited by 79
Synthesis of 17β-estradiol platinum(II) complexes: biological evaluation on breast cancer cell lines
Descôteaux, C., Provencher-Mandeville, J., Mathieu, I., Perron, V., Mandal, S. K., Asselin, É., & Bérubé, G. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2003.09.011 · Cited by 76
In vivo biodistribution of platinum-based drugs encapsulated into multi-walled carbon nanotubes
Li, J., Pant, A., Chin, C. F., Ang, W. H., Ménard‐Moyon, C., Nayak, T. R., Gibson, D., Ramaprabhu, S., Pańczyk, T., Bianco, A., et al. (2014) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2014.01.004 · Cited by 75
Kellinger, M. W., Park, G. Y., Chong, J. P. C., Lippard, S. J., & Wang, D. (2013) · Journal of the American Chemical Society · doi:10.1021/ja405475y · Cited by 73
Solid-phase synthesis of oxaliplatin–TATpeptide bioconjugates
Abramkin, S. A., Valiahdi, S. M., Jakupec, M. A., et al. (2012) · Dalton Transactions · doi:10.1039/c2dt12024k · Cited by 69
Liposomes, a promising strategy for clinical application of platinum derivatives
Zalba, S., & Garrido, M. J. (2013) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2013.778240 · Cited by 69
Pulskamp, K., Wörle‐Knirsch, J. M., Hennrich, F. H., Kern, K., & Krug, H. F. (2007) · Carbon · doi:10.1016/j.carbon.2007.06.054 · Cited by 57
Kapp, T., Dullin, A., & Gust, R. (2010) · Bioconjugate Chemistry · doi:10.1021/bc900406m · Cited by 57
Molecular Dynamics Study of Cisplatin Release from Carbon Nanotubes Capped by Magnetic Nanoparticles
Pańczyk, T., Jagusiak, A., Pastorin, G., et al. (2013) · The Journal of Physical Chemistry C · doi:10.1021/jp405593u · Cited by 56
Gagnon, V., St-Germain, M.-É., Descôteaux, C., Provencher-Mandeville, J., Parent, S., Mandal, S. K., Asselin, É., & Bérubé, G. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.09.015 · Cited by 55
Does cytotoxicity of metallointercalators correlate with cellular uptake or DNA affinity?
Davis, K. J., Carrall, J. A., Lai, B. C. H., Aldrich-Wright, J. R., Ralph, S. F., & Dillon, C. T. (2012) · Dalton Transactions · doi:10.1039/c2dt30217a · Cited by 54
Nguyen, H. P. M., Nguyen, N. H., Trân, N. Q., et al. (2014) · Journal of Nanoscience and Nanotechnology · doi:10.1166/jnn.2015.9808 · Cited by 53
A synthetic peptide mediated active targeting of cisplatin liposomes to Tie2 expressing cells
Mai, J., Song, S., Rui, M., Liu, D., Ding, Q., Peng, J., & Xu, Y. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.06.024 · Cited by 44
Anionic PAMAM dendrimers as drug delivery vehicles for transition metal-based anticancer drugs
Pisani, M. J., Wheate, N., Keene, F. R., Aldrich-Wright, J. R., & Collins, J. G. (2008) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2008.11.014 · Cited by 40
Self-citationWalker, S., Kaur, R., McInnes, F. J., et al. (2010) · Molecular Pharmaceutics · doi:10.1021/mp100191b · Cited by 39
The new platinum-based anticancer agent LA-12 induces retinol binding protein 4 in vivo
Bouchal, P., Jarkovský, J., Hrazdilová, K., Dvořáková, M., Struhárová, I., Hernychová, L., Damborský, J., Sova, P., & Vojtěšek, B. (2011) · Proteome Science · doi:10.1186/1477-5956-9-68 · Cited by 27
Moghaddas, S., Majmudar, P., Marín, R., Dezvareh, H., Qi, C., Soans, E., & Bose, R. N. (2012) · Inorganica Chimica Acta · doi:10.1016/j.ica.2012.05.040 · Cited by 25
Waalboer, D. C. J., Muns, J. A., Sijbrandi, N. J., Schasfoort, R. B. M., Haselberg, R., Somsen, G. W., Houthoff, H., & van Dongen, G. A. M. S. (2015) · ChemMedChem · doi:10.1002/cmdc.201402496 · Cited by 22
Zhao, M., Zhao, M. L., Zeng, E., Li, Y., Li, J., Cao, Q., Tan, C., Ji, L., & Mao, Z. (2014) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2014.03.012 · Cited by 14
Chu, J. J., Apps, M. G., & Wheate, N. (2014) · Supramolecular chemistry · doi:10.1080/10610278.2014.926361 · Cited by 13
Self-citationLiu, K.-J., Guan, Z.-Z., Liang, Y., Yang, X.-Q., Peng, J., Huang, H., Shao, Q.-X., Wang, M.-Z., Zhu, Y.-Z., Wu, C.-P., et al. (2014) · Archives of Medical Science · doi:10.5114/aoms.2014.44862 · Cited by 12
Cited by
Cisplatin: The first metal based anticancer drug
Ghosh, S. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.102925 · Cited by 1,751
The side effects of platinum-based chemotherapy drugs: a review for chemists
Oun, R., Moussa, Y. E., & Wheate, N. J. (2018) · Dalton Transactions · doi:10.1039/c8dt00838h · Cited by 1,737
Self-citationMetal complexes in cancer therapy – an update from drug design perspective
Ndagi, U., Mhlongo, N., & Soliman, M. (2017) · Drug Design, Development and Therapy · doi:10.2147/dddt.s119488 · Cited by 935
Platinum-based drugs: past, present and future
Dilruba, S., & Kalayda, G. V. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-2976-z · Cited by 906
FOXO Signaling Pathways as Therapeutic Targets in Cancer
Farhan, M., Wang, H., Gaur, U., Little, P. J., Xu, J., & Zheng, W. (2017) · International Journal of Biological Sciences · doi:10.7150/ijbs.20052 · Cited by 533
Metadata
- Authors
- Apps, M. G., Choi, E. H. Y., & Wheate, N. J.
- Venue
- Endocrine-Related Cancer
- Publisher
- Bioscientifica
- Published
- 2015-06-25
- Volume
- 22
- Issue
- 4
- Pages
- R219-R233
- ISSN
- 1351-0088 (ISSN-L)
- 1479-6821
- OpenAlex
- W2098241498
- Cited by
- 256
- References
- 67
- FWCI
- 12.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.